|
|||||
|
|
Design and Rationale for Randomized,Doubleblind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Patients With Diabetic Nephropathy (DN) |
|
| Authors: | LuAnn Sabounjian James Shipley Virginia Braman Mark Harnett Lijun Wu David Turnquist Philip Graham |
| Affiliation: | Concert Pharmaceuticals, Lexington, MA, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |